REGISTERED NUMBER: |
BREAS TECHNOLOGIES (UK) LIMITED |
FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 |
REGISTERED NUMBER: |
BREAS TECHNOLOGIES (UK) LIMITED |
FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 |
BREAS TECHNOLOGIES (UK) LIMITED (REGISTERED NUMBER: 09199666) |
CONTENTS OF THE FINANCIAL STATEMENTS |
FOR THE YEAR ENDED 31 DECEMBER 2023 |
Page |
Balance Sheet | 1 |
Notes to the Financial Statements | 2 |
BREAS TECHNOLOGIES (UK) LIMITED (REGISTERED NUMBER: 09199666) |
BALANCE SHEET |
31 DECEMBER 2023 |
2023 | 2022 |
Notes | £ | £ | £ | £ |
FIXED ASSETS |
Investments | 4 |
CURRENT ASSETS |
Debtors | 5 |
CREDITORS |
Amounts falling due within one year | 6 |
NET CURRENT ASSETS |
TOTAL ASSETS LESS CURRENT LIABILITIES |
CAPITAL AND RESERVES |
Called up share capital |
Capital Contribution Reserve |
Retained earnings | ( |
) | ( |
) |
SHAREHOLDERS' FUNDS |
In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered. |
The financial statements were approved by the director and authorised for issue on |
BREAS TECHNOLOGIES (UK) LIMITED (REGISTERED NUMBER: 09199666) |
NOTES TO THE FINANCIAL STATEMENTS |
FOR THE YEAR ENDED 31 DECEMBER 2023 |
1. | STATUTORY INFORMATION |
Breas Technologies (UK) Limited is a private company limited by shares. The company is registered in England under number 09199666 and the address of the registered office is Barclays Bank Chambers, Bridge Street, Stratford-upon-Avon, Warwickshire, CV37 6AH. The company's place of business is Unit A2, The Bridge Business Centre, Timothy's Bridge Road, Stratford-upon-Avon, Warwickshire, CV37 9HW. |
2. | ACCOUNTING POLICIES |
Basis of preparing the financial statements |
Preparation of consolidated financial statements |
The company has not prepared consolidated financial statements in accordance with the available exemption under section 401 of the Companies Act 2006. |
The accounts present information about the company as an individual undertaking and not about its group. |
Investments in subsidiaries |
Investments in subsidiary undertakings are recognised at cost. |
Taxation |
Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account based on the fact that group relieved losses have been paid for. |
Current or deferred taxation assets and liabilities are not discounted. |
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
Deferred tax |
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. |
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
3. | EMPLOYEES AND DIRECTORS |
The average number of employees during the year was NIL (2022 - NIL). |
BREAS TECHNOLOGIES (UK) LIMITED (REGISTERED NUMBER: 09199666) |
NOTES TO THE FINANCIAL STATEMENTS - continued |
FOR THE YEAR ENDED 31 DECEMBER 2023 |
4. | FIXED ASSET INVESTMENTS |
Shares in |
group |
undertakings |
£ |
COST |
At 1 January 2023 |
and 31 December 2023 |
NET BOOK VALUE |
At 31 December 2023 |
At 31 December 2022 |
5. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
2023 | 2022 |
£ | £ |
Amounts owed by group undertakings |
Other debtors |
6. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
2023 | 2022 |
£ | £ |
Other creditors |
7. | DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006 |
The Report of the Auditors was unqualified. |
for and on behalf of |
8. | CONTROL |
The immediate parent company is Breas Medical Holdings AB, incorporated in Sweden. |
The immediate intermediate holding company is Fosun Medical Holdings AB, a company incorporated in Sweden. Further intermediate holding companies are Fosun Industrial Co., Ltd, a company incorporated in China. The ultimate holding company is Shanghai Fosun Pharmaceutical (Group) Co., Limited a company whose shares are listed on the Main Board of the Hong Kong Stock Exchange (stock code: 2196). |
The smallest and largest group in which the company's accounts and the accounts of its subsidiary Breas Medical Limited are consolidated is that headed by Shanghai Fosun Pharmaceutical (Group) Co., Limited. |